| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/13/2005 | WO2005002575A1 Cis-imidazolines as mdm2 inhibitors |
| 01/13/2005 | WO2005002572A2 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | WO2005002571A1 Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| 01/13/2005 | WO2005002555A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| 01/13/2005 | WO2005002552A2 Benzimidazole derivatives and their use as protein kinases inhibitors |
| 01/13/2005 | WO2005002494A2 Pharmaceutical active ingredient to combat prostatic cancer |
| 01/13/2005 | WO2004072047A8 Indoles, benzimidazoles or naphhimidazoles as histone deacetylase (hdac) inhibitors |
| 01/13/2005 | WO2004069876A3 Trimeric polypeptide construct to induce an enduring t cell response |
| 01/13/2005 | WO2004006958A8 Stable pharmaceutical composition comprising erythropoietin |
| 01/13/2005 | WO2003095462A3 Platinum complexes containing chemically modified bile acids, having antitumor activity |
| 01/13/2005 | WO2003089569A3 Use of il-19, il-22 and il-24 to treat hematopoietic disorders |
| 01/13/2005 | WO2003074073A3 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 01/13/2005 | WO2003065787A8 Methods and compositions for the targeting of a systemic immune response to specific organs or tissues |
| 01/13/2005 | US20050010052 P2X7 receptor (a ligand-gated ion channel) antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases; osteoarthritis |
| 01/13/2005 | US20050010050 Antiinflammatory agents; antiarthritic agents; anticancer agents; analgesics |
| 01/13/2005 | US20050010047 Angiogenesis inhibitors; psoriasis; rheumatic disorders; chronic obstructive pulmonary disease |
| 01/13/2005 | US20050010042 Expression vector comprising nucleotide sequences comprising pro-polypeptide for use in the diagnosis, prevention and treatment of cell proliferative, inflammatory, cardiovascuar and nervous system disorders |
| 01/13/2005 | US20050009920 Taxol enhancer compounds |
| 01/13/2005 | US20050009898 New substituted indolinones, their manufacture and their use as medicaments |
| 01/13/2005 | US20050009894 Benzimidazole derivatives and their use as KDR kinase protein inhibitors |
| 01/13/2005 | US20050009872 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| 01/13/2005 | US20050009867 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/13/2005 | US20050009852 human orexin receptor antagonists; analgesics, antidiabetic agents; sleep apnea, insomnia |
| 01/13/2005 | US20050009851 Use of cyclopeta[g]quinazoline derivatives for treating cancer |
| 01/13/2005 | US20050009849 Pyridopyrimidine kinase inhibitors |
| 01/13/2005 | US20050009846 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders |
| 01/13/2005 | US20050009845 Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| 01/13/2005 | US20050009838 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/13/2005 | US20050009831 Chemical compounds |
| 01/13/2005 | US20050009826 5,6,13-trizaza- or 6,13-diazachryseno[2,3-d]-[1,3]dioxole derivatives; enzyme inhibitors; anticarcinogenic, antiproliferative agents; bactericides, fungicides |
| 01/13/2005 | US20050009825 Cytotoxic agents |
| 01/13/2005 | US20050009824 Solubilized topoisomerase poisons |
| 01/13/2005 | US20050009815 4-Aminoquinoline compounds |
| 01/13/2005 | US20050009812 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
| 01/13/2005 | US20050009808 Azabicyclo compound matrix metalloprotease inibitor and skin preparation |
| 01/13/2005 | US20050009802 Tertiary amino-substituted, e.g, 1(4),8(11),15(18),22(25)-tetrakis[(3-(dimethylamino)phenoxy)phthalocyaninato] zinc; and their use as photodynamic therapeutic and photodiagnostic agents. |
| 01/13/2005 | US20050009797 Androstane derivative having substituent in 7- abd 17--positions |
| 01/13/2005 | US20050009792 (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| 01/13/2005 | US20050009783 Adjust solubility; dissolving taxol and cyclodextrin compound in ethanol; stirring; heating |
| 01/13/2005 | US20050009759 Anticancer agents |
| 01/13/2005 | US20050009755 (74)(3S)-3-amino-1-(1-benzyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-4-yl)-5-methyl-2-heptanone for example; cysteine protease inhibitors; treating bone resorption diseases such as osteoporosis |
| 01/13/2005 | US20050009751 Pentapeptide compounds and uses related thereto |
| 01/13/2005 | US20050009741 Copolymer made by depolymerizing chitosan and acylating such as with glutaryl and propionyl groups; mixture with peptides such as buserelin, deslorelin, histrelin; ionic conjugate with parathyroid hormone |
| 01/13/2005 | US20050009738 Interleukin with nucleic acid carrier |
| 01/13/2005 | US20050009185 Using replication defcetive hepadnaviral plasmid comprising nucleotide sequences coding chemokines and/or cytokines for use in the treatment of liver disorders; tissue engineering and gene therapy |
| 01/13/2005 | US20050009184 Humanised baculovirus |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009073 Polyamide nucleic acid derivatives, and agents, and processes for preparing them |
| 01/13/2005 | US20050009043 Prodrugs of phosphonate nucleotide analogues |
| 01/13/2005 | US20050009025 A soluble T cell receptor for use as diagnostic indicator of infection and autoimmune diseases |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008688 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems |
| 01/13/2005 | US20050008655 Useful as barrier applied to skin; chemical and radiation resistance; skin disorders; autoimmune diseases; antitumor agents; topical applying |
| 01/13/2005 | US20050008653 In situ binding of polypeptide to stabilizer; induction apoptosis |
| 01/13/2005 | US20050008650 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability |
| 01/13/2005 | US20050008647 Induction antiidiotype antibodies |
| 01/13/2005 | US20050008643 Diagnostic methods and agents |
| 01/13/2005 | US20050008637 Cancer therapy; antiinflammatory agents; autoimmune disease |
| 01/13/2005 | US20050008636 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 01/13/2005 | US20050008635 Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods |
| 01/13/2005 | US20050008631 Anti-hiv and anti-tumor peptides and fragments of lysozyme |
| 01/13/2005 | US20050008623 In vitro production of dendritic cells from CD14+ monocytes |
| 01/13/2005 | US20050008614 Herpes virus; papillomas virus; skin; urogenital systems; topical applying; spray dressing |
| 01/13/2005 | US20050008574 Use of intravenous contrast media for projection mammography |
| 01/13/2005 | US20050008573 Diagnosis of tumors; in vivo imaging |
| 01/13/2005 | US20050008568 Complex containing dithiocarbamate compound |
| 01/13/2005 | DE10328251A1 Pharmazeutischer Wirkstoff Active Pharmaceutical Ingredient |
| 01/13/2005 | CA2756586A1 Modulation of survivin expression |
| 01/13/2005 | CA2532066A1 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | CA2531327A1 Compounds and therapeutical use thereof |
| 01/13/2005 | CA2531321A1 Rna processing protein complexes and uses thereof |
| 01/13/2005 | CA2531238A1 Polypeptides having binding affinity for her2 |
| 01/13/2005 | CA2531142A1 Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| 01/13/2005 | CA2531050A1 Pharmaceutical compounds |
| 01/13/2005 | CA2530884A1 Trp-p8 active compounds and therapeutic treatment methods |
| 01/13/2005 | CA2530317A1 Pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 01/13/2005 | CA2530316A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 01/13/2005 | CA2530116A1 Use of roscovitine for treating lymphocytic leukemia |
| 01/13/2005 | CA2530114A1 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 01/13/2005 | CA2529558A1 Agent inducing increase in bone mass |
| 01/13/2005 | CA2529510A1 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 01/13/2005 | CA2529244A1 Rapamycin resistant t cells and therapeutic uses thereof |
| 01/13/2005 | CA2529057A1 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| 01/13/2005 | CA2528084A1 Sppls as modifiers of the p53 pathway and methods of use |
| 01/13/2005 | CA2527908A1 Mylks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2527905A1 Nadks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2525968A1 Metabolites of tricyclic amides useful for inhibition of g-protein function and methods of treatment of proliferative diseases |
| 01/13/2005 | CA2524495A1 Modulation of survivin expression |
| 01/12/2005 | EP1496116A1 Anticancer agents using vero toxin variants |
| 01/12/2005 | EP1496109A1 Process for producing cytotoxic lymphocyte |
| 01/12/2005 | EP1496076A1 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound |
| 01/12/2005 | EP1496060A1 Antitumoral analogs of ET-743 |
| 01/12/2005 | EP1495767A1 Immunoadjuvant |
| 01/12/2005 | EP1495766A1 Factor VII activating protease (FSAP) derived polypeptides for the treatment of angiogenesis-related disorders |
| 01/12/2005 | EP1495756A1 Severe sepsis preventive therapeutic agent |
| 01/12/2005 | EP1495754A2 Method and composition for treating cancers |
| 01/12/2005 | EP1495327A2 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen |
| 01/12/2005 | EP1495322A2 Heteroclitic analogs and related methods |
| 01/12/2005 | EP1495130A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/12/2005 | EP1495123A1 Erbb3 based methods and compositions for treating neoplasms |